TABLE 2.
Assay (total)a | No. of positiveb samples/no. of tested samples
|
Sensitivity (%) | ||||||
---|---|---|---|---|---|---|---|---|
Skin biopsy specimens | Bone marrow samples | Blood samples | Duodenal biopsy specimensc | Gastric biopsy specimens | Lesion aspirates | Total | ||
In vitro cultivation (38) | 6/9 | 3/5 | 1/1 | 1/1 | 1/1 | NA | 12/17 | 70.59 |
Serology (16) | 5/9 | 3/4 | 0/1 | NA | NA | NA | 8/14 | 57.14 |
LEG PCR (50) | 10/16d | 7/7 | 2/2 | 2/2 | 1/1 | 1/1 | 23/29 | 79.31 (100)d |
SSU-ITS PCR (29)e | 7/16 | 3/7 | 1/2 | 2/2 | 1/1 | 1/1 | 15/29 | 51.71 |
Miniexon PCR (50) | 16/16 | 4/7 | 2/2 | 2/2 | 1/1 | 1/1 | 26/29 | 89.66 |
Total number of samples subjected to each assay.
Leishmaniasis confirmed by at least one of the diagnostic tests.
NA, not applicable.
All negative samples were subsequently shown to be infected with New World species; therefore, sensitivity for Old World species was adjusted to 100%.
Only samples that were previously identified as positive by other assays were tested.